Breast Cancer

MONALEESA-2: the beauty of striving for overall survival goals in postmenopausal metastatic breast cancer

Sponsored by Novartis

Presented at ESMO 2021, the protocol-specified final analysis of the Phase III MONALEESA-2 trial demonstrated an overall survival (OS) benefit with CDK4/6 inhibitor ribociclib plus aromatase inhibitor letrozole in postmenopausal women with hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) negative advanced breast cancer.1-3 Following the presentation of the MONALEESA-2 data, the limbic spoke ...

Already a member?

Login to keep reading.

© 2022 the limbic